- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03541824
Reducing Suicide Risk Associated With Weight Loss
May 29, 2018 updated by: Pamela Keel, Florida State University
The purpose of this study is to examine the efficacy of an intervention aimed at promoting a healthy lifestyle and reducing risk factors associated with eating pathology, nonsuicidal self-injury, and suicidal behavior.
We are also interested in assessing whether this intervention has the potential to prevent future symptoms of eating problems and self-harm urges and behaviors.
The broader goal of this research is to identify factors that may help us better understand the prevention of self-harm behaviors and develop more effective treatments for these problems.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The current study was designed as a proof-of-concept study to test the association between weight suppression (WS; difference between one's highest and lowest weight) and non-suicidal self-injury (NSSI).
Previous research has found an association between current WS and lifetime NSSI and that this association was mediated by depressive symptoms and drive for thinness.
The current study therefore modified an existing online cognitive dissonance-based program (the e-Body Project) using mixed gender content (from the Body Project 4 All scripts) to target posited mediators, i.e., depressive symptoms and weight and shape concerns, in a sample of individuals with WS and engagement in current NSSI.
Study Type
Interventional
Enrollment (Actual)
59
Phase
- Not Applicable
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 18-65 years old
- At least 5 pounds weight suppression
- Engaged in non-suicidal self-injury at least once in past month
Exclusion Criteria:
- Indicated being "sure" of suicide attempt on eligibility screener
- Live outside of the United States
- Currently pregnant
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Body Acceptance Program
The Body Acceptance Program (BAP) is the active condition.
Participants engage in an online intervention during which they complete online and offline activities designed to challenge the appearance-ideal.
|
The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
Other Names:
|
|
No Intervention: Waitlist control
Participants in the waitlist control group completed baseline and follow-up assessments with no intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline on the Self-Injurious Thoughts and Behaviors Interview-Short Form (self-report) at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Self-harm frequency and likelihood
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change from baseline on the "Body Esteem Scale: Appearance" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's appearance; scores are summed and range from 0-40, higher scores indicate greater appearance esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the "Body Esteem Scale: Weight" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's weight; scores are summed and range from 0-32, higher scores indicate greater weight esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the "Body Esteem Scale: Attribution" subscale at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Feelings about one's characteristics; scores are summed and range from 0-20, higher scores indicate greater self-esteem
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Beck Depression Inventory II at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Depressive symptoms
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Body Shape Questionnaire (8-item version #3) at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Assessment of weight and shape concerns
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
|
Change from baseline on the Positive and Negative Affect Schedule at follow-up
Time Frame: Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Captures current positive and negative affect
|
Pre-assessment and post-assessment (after intervention or two weeks from baseline)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pamela Keel, Ph.D., Florida State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 1, 2016
Primary Completion (Actual)
March 20, 2017
Study Completion (Actual)
March 20, 2017
Study Registration Dates
First Submitted
December 3, 2017
First Submitted That Met QC Criteria
May 29, 2018
First Posted (Actual)
May 31, 2018
Study Record Updates
Last Update Posted (Actual)
May 31, 2018
Last Update Submitted That Met QC Criteria
May 29, 2018
Last Verified
May 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10274002
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Participants' responses to measures collected during the study will be shared with the funding body, the Military Suicide Research Consortium, as part of their Core Data Elements project, a centralized database of data from all MSRC funded projects.
All participant responses are deidentified and are uploaded to the MSRC through a secure upload.
IPD Sharing Time Frame
Study protocol and informed consent forms will be shared during and after study recruitment.
Participants' responses to measures collected during the study will be shared at the end of participant completion.
IPD Sharing Access Criteria
Once data is uploaded to the Core Data Element (CDE) project, it may be combined with data from other projects for greater power to conduct statistical analyses, including, but not limited to, regression analyses and scale development.
The following link (https://msrc.fsu.edu/members/request-access-msrc-database)
describes steps that investigators must take in order to access the data.
In addition, the study protocols and consent forms are reviewed and approved by the Department of Defense Human Research Protection Office (HRPO) throughout the study.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.